MedWatch

Bavarian: The clock is ticking for BMS

The first quarter went as expected for Denmark’s Bavarian Nordic. The clinical program with the prostate hope Prostvac will continue in progress. This means that the Danish company will also come closer to more millions from US company Bristol-Meyers Squibb. Meanwhile, the company’s CFO makes a plea to the world concerning the Zika virus.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us free for 14 days

Get 14 days free trial access

Frontpage right now

Svensk Novo-selskab går tilbage på både top- og bundlinje

Både omsætning og indtjening er faldet i tredje kvartal for det svenske medicinalselskab Orexo, som Novo Holdings ejer en fjerdedel af. Selskabet styrer dog fortsat mod et nyt år med plus på bundlinjen, og der er lagt i ovnen til et endnu bedre 2018.

Latest Top picks in English

Related articles